
-
Sutro Biopharma NASDAQ:STRO Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Location: 310 Utah Ave Ste 150, California, 94080-6803, US | Website: www.sutrobio.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-218.1M
Cash
316.9M
Avg Qtr Burn
-47.89M
Short % of Float
7.66%
Insider Ownership
4.11%
Institutional Own.
79.73%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Platinum-resistant ovarian cancer | Phase 3 Data readout | |
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Acute myeloid leukemia | Phase 2/3 Update | |
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) + bevacizumab Details Ovarian cancer, Cancer, Endometrial cancer | Phase 1b Update | |
M1231 (MUC1-EGFR Bispecific ADC) Details Solid tumor/s, Esophageal cancer, Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
STRO-001 (BN301) (CD74-Targeting ADC) Details Cancer, B-cell lymphoma, Follicular lymphoma, Lymphoma, Mantle cell lymphoma | Failed Discontinued |